デフォルト表紙
市場調査レポート
商品コード
1061251

世界の非アルコール性脂肪性肝炎(NASH)市場:考察と予測 (2028年まで)

Global Nonalcoholic Steatohepatitis (NASH) Market Insights and Forecast to 2028

出版日: | 発行: QYResearch | ページ情報: 英文 110 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
世界の非アルコール性脂肪性肝炎(NASH)市場:考察と予測 (2028年まで)
出版日: 2022年03月01日
発行: QYResearch
ページ情報: 英文 110 Pages
納期: 2~3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、非アルコール性脂肪性肝炎(NASH) (Nonalcoholic Steatohepatitis (NASH)) 市場について調査しており、市場規模や動向の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析:タイプ別
    • 世界の非アルコール性脂肪性肝炎(NASH)の市場規模成長率:タイプ別, 2017 VS 2021 VS 2028
    • Obeticholic acid(OCA)
    • Selonsertib
  • 市場:アプリケーション別
    • 世界の非アルコール性脂肪性肝炎(NASH)の市場規模成長率:アプリケーション別, 2017 VS 2021 VS 2028
    • Hospital Pharmacy
    • Online Provider
    • Retail Pharmacy
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界の非アルコール性脂肪性肝炎(NASH)の市場展望 (2017-2028)
  • 非アルコール性脂肪性肝炎(NASH)の市場成長トレンド:地域別
    • 非アルコール性脂肪性肝炎(NASH) 市場規模:地域別: 2017 VS 2021 VS 2028
    • 非アルコール性脂肪性肝炎(NASH)の市場規模実績:地域別 (2017-2022)
    • 非アルコール性脂肪性肝炎(NASH)の市場規模予測:地域別 (2023-2028)
  • 非アルコール性脂肪性肝炎(NASH) 市場動向
    • 非アルコール性脂肪性肝炎(NASH) 業界動向
    • 非アルコール性脂肪性肝炎(NASH) 市場の促進要因
    • 非アルコール性脂肪性肝炎(NASH) 市場の課題
    • 非アルコール性脂肪性肝炎(NASH) 市場の抑制要因

第3章 競合情勢:主要企業別

  • 世界の非アルコール性脂肪性肝炎(NASH)の上位企業:収益別
    • 世界の非アルコール性脂肪性肝炎(NASH)の上位企業:収益別 (2017-2022)
    • 世界の非アルコール性脂肪性肝炎(NASH)の収益シェア:企業別 (2017-2022)
  • 世界の非アルコール性脂肪性肝炎(NASH)の市場シェア:企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング:非アルコール性脂肪性肝炎(NASH)の収益
  • 世界の非アルコール性脂肪性肝炎(NASH) 市場集中度
    • 世界の非アルコール性脂肪性肝炎(NASH) 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業: 非アルコール性脂肪性肝炎(NASH)の収益 2021
  • 非アルコール性脂肪性肝炎(NASH)の主要企業の本社および事業エリア
  • 主要企業 非アルコール性脂肪性肝炎(NASH)の製品ソリューションおよびサービス
  • 市場参入時期: 非アルコール性脂肪性肝炎(NASH) 市場
  • M&A, 拡張計画

第4章 非アルコール性脂肪性肝炎(NASH) 内訳データ:タイプ別

  • 世界の非アルコール性脂肪性肝炎(NASH)の市場規模実績:タイプ別 (2017-2022)
  • 世界の非アルコール性脂肪性肝炎(NASH)の市場規模予測:タイプ別 (2023-2028)

第5章 非アルコール性脂肪性肝炎(NASH) 内訳データ:アプリケーション別

  • 世界の非アルコール性脂肪性肝炎(NASH)の市場規模実績:アプリケーション別 (2017-2022)
  • 世界の非アルコール性脂肪性肝炎(NASH)の市場規模予測:アプリケーション別 (2023-2028)

第6章 北米

  • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模 (2017-2028)
  • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別
    • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2017-2022)
    • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2023-2028)
    • 北米の非アルコール性脂肪性肝炎(NASH)の市場シェア:タイプ別 (2017-2028)
  • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別
    • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2017-2022)
    • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2023-2028)
    • 北米の非アルコール性脂肪性肝炎(NASH)の市場シェア:アプリケーション別 (2017-2028)
  • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:国別
    • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2017-2022)
    • 北米の非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2023-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模 (2017-2028)
  • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別
    • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2017-2022)
    • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2023-2028)
    • 欧州の非アルコール性脂肪性肝炎(NASH)の市場シェア:タイプ別 (2017-2028)
  • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別
    • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2017-2022)
    • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2023-2028)
    • 欧州の非アルコール性脂肪性肝炎(NASH)の市場シェア:アプリケーション別 (2017-2028)
  • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:国別
    • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2017-2022)
    • 欧州の非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2023-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 アジア太平洋地域

  • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模 (2017-2028)
  • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2017-2022)
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2023-2028)
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH)の市場シェア:タイプ別 (2017-2028)
  • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2017-2022)
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2023-2028)
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH)の市場シェア:アプリケーション別 (2017-2028)
  • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:地域別
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:地域別 (2017-2022)
    • アジア太平洋地域 非アルコール性脂肪性肝炎(NASH) 市場規模:地域別 (2023-2028)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模 (2017-2028)
  • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2017-2022)
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2023-2028)
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH)の市場シェア:タイプ別 (2017-2028)
  • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2017-2022)
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2023-2028)
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH)の市場シェア:アプリケーション別 (2017-2028)
  • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:国別
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2017-2022)
    • ラテンアメリカの非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2023-2028)
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模 (2017-2028)
  • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2017-2022)
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:タイプ別 (2023-2028)
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH)の市場シェア:タイプ別 (2017-2028)
  • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2017-2022)
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:アプリケーション別 (2023-2028)
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH)の市場シェア:アプリケーション別 (2017-2028)
  • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:国別
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2017-2022)
    • 中東・アフリカの非アルコール性脂肪性肝炎(NASH) 市場規模:国別 (2023-2028)
    • トルコ
    • サウジアラビア
    • UAE

第11章 主要企業のプロファイル

  • AstraZeneca
  • Arena Pharmaceuticals
  • GSK
  • Novo Nordisk
  • Roche
  • Vivus
  • Arisaph Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead

第12章 アナリストによる分析/結論

第13章 付録

図表

LIST OF TABLES

List of Tables

  • Table 1. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
  • Table 2. Key Players of Obeticholic acid(OCA)
  • Table 3. Key Players of Selonsertib
  • Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
  • Table 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
  • Table 6. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2017-2022) & (US$ Million)
  • Table 7. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2017-2022)
  • Table 8. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2023-2028) & (US$ Million)
  • Table 9. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region (2023-2028)
  • Table 10. Nonalcoholic Steatohepatitis (NASH) Market Trends
  • Table 11. Nonalcoholic Steatohepatitis (NASH) Market Drivers
  • Table 12. Nonalcoholic Steatohepatitis (NASH) Market Challenges
  • Table 13. Nonalcoholic Steatohepatitis (NASH) Market Restraints
  • Table 14. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Players (2017-2022) & (US$ Million)
  • Table 15. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players (2017-2022)
  • Table 16. Global Top Nonalcoholic Steatohepatitis (NASH) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2021)
  • Table 17. Ranking of Global Top Nonalcoholic Steatohepatitis (NASH) Companies by Revenue (US$ Million) in 2021
  • Table 18. Global 5 Largest Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue (CR5 and HHI) & (2017-2022)
  • Table 19. Key Players Headquarters and Area Served
  • Table 20. Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
  • Table 21. Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
  • Table 22. Mergers & Acquisitions, Expansion Plans
  • Table 23. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 24. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2017-2022)
  • Table 25. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 26. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type (2023-2028)
  • Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 28. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Application (2017-2022)
  • Table 29. Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 30. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Application (2023-2028)
  • Table 31. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 32. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 33. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 34. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 35. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 36. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 37. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 38. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 39. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 40. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 41. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 42. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 43. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 44. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 45. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 46. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 47. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2017-2022) & (US$ Million)
  • Table 48. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2023-2028) & (US$ Million)
  • Table 49. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 50. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 51. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 52. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 53. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 54. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 55. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 56. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 57. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 58. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 59. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 60. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 61. AstraZeneca Company Details
  • Table 62. AstraZeneca Business Overview
  • Table 63. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product
  • Table 64. AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 65. AstraZeneca Recent Developments
  • Table 66. Arena Pharmaceuticals Company Details
  • Table 67. Arena Pharmaceuticals Business Overview
  • Table 68. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
  • Table 69. Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 70. Arena Pharmaceuticals Recent Developments
  • Table 71. GSK Company Details
  • Table 72. GSK Business Overview
  • Table 73. GSK Nonalcoholic Steatohepatitis (NASH) Product
  • Table 74. GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 75. GSK Recent Developments
  • Table 76. Novo Nordisk Company Details
  • Table 77. Novo Nordisk Business Overview
  • Table 78. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product
  • Table 79. Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 80. Novo Nordisk Recent Developments
  • Table 81. Roche Company Details
  • Table 82. Roche Business Overview
  • Table 83. Roche Nonalcoholic Steatohepatitis (NASH) Product
  • Table 84. Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 85. Roche Recent Developments
  • Table 86. Vivus Company Details
  • Table 87. Vivus Business Overview
  • Table 88. Vivus Nonalcoholic Steatohepatitis (NASH) Product
  • Table 89. Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 90. Vivus Recent Developments
  • Table 91. Arisaph Pharmaceuticals Company Details
  • Table 92. Arisaph Pharmaceuticals Business Overview
  • Table 93. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
  • Table 94. Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 95. Arisaph Pharmaceuticals Recent Developments
  • Table 96. Cempra Pharmaceuticals Company Details
  • Table 97. Cempra Pharmaceuticals Business Overview
  • Table 98. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
  • Table 99. Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 100. Cempra Pharmaceuticals Recent Developments
  • Table 101. Galectin Therapeutics Company Details
  • Table 102. Galectin Therapeutics Business Overview
  • Table 103. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product
  • Table 104. Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 105. Galectin Therapeutics Recent Developments
  • Table 106. Galmed Pharmaceuticals Company Details
  • Table 107. Galmed Pharmaceuticals Business Overview
  • Table 108. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product
  • Table 109. Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 110. Galmed Pharmaceuticals Recent Developments
  • Table 111. Genfit Company Details
  • Table 112. Genfit Business Overview
  • Table 113. Genfit Nonalcoholic Steatohepatitis (NASH) Product
  • Table 114. Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 115. Genfit Recent Developments
  • Table 116. Gilead Company Details
  • Table 117. Gilead Business Overview
  • Table 118. Gilead Nonalcoholic Steatohepatitis (NASH) Product
  • Table 119. Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022) & (US$ Million)
  • Table 120. Gilead Recent Developments
  • Table 121. Research Programs/Design for This Report
  • Table 122. Key Data Information from Secondary Sources
  • Table 123. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Type: 2021 VS 2028
  • Figure 2. Obeticholic acid(OCA) Features
  • Figure 3. Selonsertib Features
  • Figure 4. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application: 2021 VS 2028
  • Figure 5. Hospital Pharmacy Case Studies
  • Figure 6. Online Provider Case Studies
  • Figure 7. Retail Pharmacy Case Studies
  • Figure 8. Nonalcoholic Steatohepatitis (NASH) Report Years Considered
  • Figure 9. Global Nonalcoholic Steatohepatitis (NASH) Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 10. Global Nonalcoholic Steatohepatitis (NASH) Market Size, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Region: 2021 VS 2028
  • Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Players in 2021
  • Figure 13. Global Top Nonalcoholic Steatohepatitis (NASH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2021)
  • Figure 14. The Top 10 and 5 Players Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2021
  • Figure 15. North America Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 16. North America Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2017-2028)
  • Figure 17. North America Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Application (2017-2028)
  • Figure 18. North America Nonalcoholic Steatohepatitis (NASH) Market Size Share by Country (2017-2028)
  • Figure 19. United States Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 20. Canada Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 21. Europe Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 22. Europe Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2017-2028)
  • Figure 23. Europe Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Application (2017-2028)
  • Figure 24. Europe Nonalcoholic Steatohepatitis (NASH) Market Size Share by Country (2017-2028)
  • Figure 25. Germany Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 26. France Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 27. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 28. Italy Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 29. Russia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 30. Nordic Countries Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 31. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 32. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2017-2028)
  • Figure 33. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Application (2017-2028)
  • Figure 34. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Size Share by Region (2017-2028)
  • Figure 35. China Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 36. Japan Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 37. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 38. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 39. India Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 40. Australia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 41. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 42. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2017-2028)
  • Figure 43. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Application (2017-2028)
  • Figure 44. Latin America Nonalcoholic Steatohepatitis (NASH) Market Size Share by Country (2017-2028)
  • Figure 45. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 46. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 47. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 48. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2017-2028)
  • Figure 49. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Application (2017-2028)
  • Figure 50. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size Share by Country (2017-2028)
  • Figure 51. Turkey Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 52. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 53. UAE Nonalcoholic Steatohepatitis (NASH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 54. AstraZeneca Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 55. Arena Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 56. GSK Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 57. Novo Nordisk Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 58. Roche Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 59. Vivus Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 60. Arisaph Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 61. Cempra Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 62. Galectin Therapeutics Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 63. Galmed Pharmaceuticals Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 64. Genfit Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 65. Gilead Revenue Growth Rate in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
  • Figure 66. Bottom-up and Top-down Approaches for This Report
  • Figure 67. Data Triangulation
  • Figure 68. Key Executives Interviewed
目次

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.

Market Analysis and Insights: Global Nonalcoholic Steatohepatitis (NASH) Market

The global Nonalcoholic Steatohepatitis (NASH) market size is projected to reach US$ 46230 million by 2028, from US$ 3064.2 million in 2021, at a CAGR of 46.7% during 2022-2028.

NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nonalcoholic Steatohepatitis (NASH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nonalcoholic Steatohepatitis (NASH) market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nonalcoholic Steatohepatitis (NASH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nonalcoholic Steatohepatitis (NASH) market.

Global Nonalcoholic Steatohepatitis (NASH) Scope and Market Size

Nonalcoholic Steatohepatitis (NASH) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Steatohepatitis (NASH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

  • Obeticholic acid(OCA)
  • Selonsertib

Segment by Application

  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy

By Company

  • AstraZeneca
  • Arena Pharmaceuticals
  • GSK
  • Novo Nordisk
  • Roche
  • Vivus
  • Arisaph Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead

By Region

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

TABLE OF CONTENTS

1 Report Business Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Obeticholic acid(OCA)
    • 1.2.3 Selonsertib
  • 1.3 Market by Application
    • 1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Hospital Pharmacy
    • 1.3.3 Online Provider
    • 1.3.4 Retail Pharmacy
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Nonalcoholic Steatohepatitis (NASH) Market Perspective (2017-2028)
  • 2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Region
    • 2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Region (2017-2022)
    • 2.2.3 Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Region (2023-2028)
  • 2.3 Nonalcoholic Steatohepatitis (NASH) Market Dynamics
    • 2.3.1 Nonalcoholic Steatohepatitis (NASH) Industry Trends
    • 2.3.2 Nonalcoholic Steatohepatitis (NASH) Market Drivers
    • 2.3.3 Nonalcoholic Steatohepatitis (NASH) Market Challenges
    • 2.3.4 Nonalcoholic Steatohepatitis (NASH) Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue
    • 3.1.1 Global Top Nonalcoholic Steatohepatitis (NASH) Players by Revenue (2017-2022)
    • 3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Players (2017-2022)
  • 3.2 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Nonalcoholic Steatohepatitis (NASH) Revenue
  • 3.4 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio
    • 3.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Nonalcoholic Steatohepatitis (NASH) Revenue in 2021
  • 3.5 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
  • 3.6 Key Players Nonalcoholic Steatohepatitis (NASH) Product Solution and Service
  • 3.7 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Type

  • 4.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Type (2017-2022)
  • 4.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Type (2023-2028)

5 Nonalcoholic Steatohepatitis (NASH) Breakdown Data by Application

  • 5.1 Global Nonalcoholic Steatohepatitis (NASH) Historic Market Size by Application (2017-2022)
  • 5.2 Global Nonalcoholic Steatohepatitis (NASH) Forecasted Market Size by Application (2023-2028)

6 North America

  • 6.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
  • 6.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 6.2.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
    • 6.2.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
    • 6.2.3 North America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
  • 6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
    • 6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
    • 6.3.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
    • 6.3.3 North America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
  • 6.4 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
    • 6.4.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
    • 6.4.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
    • 6.4.3 U.S.
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
  • 7.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 7.2.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
    • 7.2.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
    • 7.2.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
  • 7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application
    • 7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
    • 7.3.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
    • 7.3.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
  • 7.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
    • 7.4.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
    • 7.4.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 Asia-Pacific

  • 8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
  • 8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 8.2.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
    • 8.2.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
    • 8.2.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
  • 8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application
    • 8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
    • 8.3.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
    • 8.3.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
  • 8.4 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
    • 8.4.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2017-2022)
    • 8.4.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2023-2028)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
  • 9.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 9.2.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
    • 9.2.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
    • 9.2.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
  • 9.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application
    • 9.3.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
    • 9.3.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
    • 9.3.3 Latin America Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
  • 9.4 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
    • 9.4.1 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
    • 9.4.2 Latin America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size (2017-2028)
  • 10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 10.2.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2017-2022)
    • 10.2.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2023-2028)
    • 10.2.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Type (2017-2028)
  • 10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application
    • 10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2017-2022)
    • 10.3.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2023-2028)
    • 10.3.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2017-2028)
  • 10.4 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
    • 10.4.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2017-2022)
    • 10.4.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2023-2028)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Company Details
    • 11.1.2 AstraZeneca Business Overview
    • 11.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.1.4 AstraZeneca Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.1.5 AstraZeneca Recent Developments
  • 11.2 Arena Pharmaceuticals
    • 11.2.1 Arena Pharmaceuticals Company Details
    • 11.2.2 Arena Pharmaceuticals Business Overview
    • 11.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.2.4 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.2.5 Arena Pharmaceuticals Recent Developments
  • 11.3 GSK
    • 11.3.1 GSK Company Details
    • 11.3.2 GSK Business Overview
    • 11.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.3.4 GSK Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.3.5 GSK Recent Developments
  • 11.4 Novo Nordisk
    • 11.4.1 Novo Nordisk Company Details
    • 11.4.2 Novo Nordisk Business Overview
    • 11.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.4.4 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.4.5 Novo Nordisk Recent Developments
  • 11.5 Roche
    • 11.5.1 Roche Company Details
    • 11.5.2 Roche Business Overview
    • 11.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.5.4 Roche Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.5.5 Roche Recent Developments
  • 11.6 Vivus
    • 11.6.1 Vivus Company Details
    • 11.6.2 Vivus Business Overview
    • 11.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.6.4 Vivus Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.6.5 Vivus Recent Developments
  • 11.7 Arisaph Pharmaceuticals
    • 11.7.1 Arisaph Pharmaceuticals Company Details
    • 11.7.2 Arisaph Pharmaceuticals Business Overview
    • 11.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.7.4 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.7.5 Arisaph Pharmaceuticals Recent Developments
  • 11.8 Cempra Pharmaceuticals
    • 11.8.1 Cempra Pharmaceuticals Company Details
    • 11.8.2 Cempra Pharmaceuticals Business Overview
    • 11.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.8.4 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.8.5 Cempra Pharmaceuticals Recent Developments
  • 11.9 Galectin Therapeutics
    • 11.9.1 Galectin Therapeutics Company Details
    • 11.9.2 Galectin Therapeutics Business Overview
    • 11.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.9.4 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.9.5 Galectin Therapeutics Recent Developments
  • 11.10 Galmed Pharmaceuticals
    • 11.10.1 Galmed Pharmaceuticals Company Details
    • 11.10.2 Galmed Pharmaceuticals Business Overview
    • 11.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.10.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.10.5 Galmed Pharmaceuticals Recent Developments
  • 11.11 Genfit
    • 11.11.1 Genfit Company Details
    • 11.11.2 Genfit Business Overview
    • 11.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.11.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.11.5 Genfit Recent Developments
  • 11.12 Gilead
    • 11.12.1 Gilead Company Details
    • 11.12.2 Gilead Business Overview
    • 11.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Introduction
    • 11.12.4 Gilead Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2017-2022)
    • 11.12.5 Gilead Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer